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Objectives: To confirmwhether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life
of single-dosenevirapineandto investigate itseffectonthedevelopmentofnevirapine resistance inpregnant,HIV-
infected women.
Methods: In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant
women ≥18 years old from Zambia and Tanzania and with CD4 cell counts .350 cells/mm3 were randomized
1:1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovu-
dine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for
7 days post-delivery) group. Primary endpoints were the pharmacokinetics of and resistance to nevirapine.
Results: Thirty-five and 37womenwere allocated to the control and intervention groups, withmedian (IQR) ages
of 27 (23–31) and 27 (23–33) years, respectively. Twenty-three and 23 women had detectable nevirapine levels
at delivery and subsequent samples in the control and the intervention groups, respectively. Geometric mean
(GM) (95% CI) plasma levels of nevirapine at delivery were 1.02 (0.58–1.78) mg/L and 1.14 (0.70–1.86) mg/L
in the control and intervention groups, respectively (P¼0.76). One week after delivery, 0/23 (0%) and 15/22
(68%) control and intervention mothers, respectively, had undetectable levels of nevirapine (,0.05 mg/L;
P,0.001). One week later, the figures were 10/21 (48%) and 18/19 (95%) mothers, respectively (P¼0.002). The
GM (95% CI) half-life of nevirapine was 63.2 (52.8–75.7) versus 25.5 (21.6–30.1) h in the control group versus
the intervention group (P,0.001). New nevirapine mutations were found in 0/20 (0%) intervention-group
mothers versus 1/21 (5%) control-group mothers. Overall, there was no difference in adverse events reported
between the control and intervention arms (P. 0.28).
Conclusions: Adding 7 days of an enzyme inducer to single-dose nevirapine to preventmother-to-child transmis-
sion of HIV significantly reduced subtherapeutic nevirapine levels by shortening the half-life of nevirapine. As pro-
longed subtherapeutic nevirapine dosage leads to the emergence of resistance, single-dose nevirapine could be
used with phenytoin as an alternative if other ARVs were unavailable.
Keywords: prevention of mother-to-child transmission of HIV, Africa, PK, nevirapine
Introduction
While the risk of HIVmother-to-child transmission (MTCT) is 20%–
40% without treatment,1,2 a simple cheap intervention—single-
dose nevirapine at the onset of labour—reduces MTCT by
50%.1,3 Itsmajor disadvantage is the development of nevirapine
resistance in bothmothers (1%–69%)and infants,4mostprobably
due to its longeliminationhalf-life (61 h),5–7which leads to several
days to weeks of subtherapeutic plasma concentrations, coupled
with its low genetic barrier to resistance.8 Newly emergent
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resistant HIVmaybe transmitted to the infant or to others, limiting
their treatment options, andmayalso reduce the efficacyof future
combination antiretroviral therapy (cART) in the mother.9
Given its simplicity and efficacy, single-dose nevirapine is never-
theless still endorsed by theWHOas part of the regimen for preven-
tion ofMTCT (pMTCT) in resource-limited settings, when cART (WHO
Option B/B+) is not feasible or not available. To cover the prolonged
presence of subtherapeutic plasma concentrations of nevirapine
after single-dose nevirapine at the onset of labour, Option A of the
WHO (2012) guidelines recommend adding zidovudine/lamivudine
for 7 days post-partum.10,11 This approach reduces the develop-
ment of resistance to 4%–16%,4 but does not fully eliminate it.
Nevirapine is extensivelymetabolized in the liver bycytochrome
P450 (CYP) isoenzymes 3A4 and 2B6.12 A pharmacological, rather
than antiretroviral (ARV), approach of adding a CYP3A4 enzyme
inducer has been shown to decrease the elimination half-life of
nevirapine in healthy women,13 the greatest reductions being
seen with carbamazepine and phenytoin. In our previous trial
(VITA-1), theadditionof single-dosecarbamazepine tosingle-dose
nevirapine at the onset of labour also significantly reduced plasma
concentrations of nevirapine 1 week after delivery in HIV-infected
women, with a trend towards fewer resistance mutations.14
The CYP3A4 enzyme inducer phenytoin is a low-cost, widely
available anticonvulsant and antiarrhythmic drug, which is not
secreted into breast milk in clinically important amounts (in con-
trast to carbamazepine) and can therefore be safely given to
breastfeeding mothers.15 In this pilot study, we investigated the
impact of 7 days of phenytoin on the pharmacokinetics of and de-
velopment of resistance to nevirapine after single-dose nevirapine
asacomponentofARVprophylaxis for pMTCT (theVITA-2 trial). The
hypothesis was that 7 days of phenytoin would reduce the elimin-
ationhalf-lifeofnevirapineandhence theemergenceofnevirapine
resistance mutations.
Methods
Study participants
Participantswere recruited fromthePasuaandMajengoantenatal clinics in
Moshi, Tanzania,andtheUniversityTeachingHospital in Lusaka,Zambia.Eli-
gible HIV-infected pregnant women were aged ≥18 years, ARV-naive,
starting ARV prophylaxis for pMTCT, not intending to relocate during study
participation and willing to attend follow-up visits. Exclusion criteria were
serious illness requiring systemic treatment or hospitalization, the use of
concomitant medication that might interfere with ARVs or phenytoin, or a
CD4 cell count ,350 cells/mm3 (making the women eligible for cART).
All the women gave written informed consent; illiterate patients gave
oral consent documented by their own thumbprint and a witness. The
study was approved by the institutional review boards of the Kilimanjaro
Christian Medical University College, Moshi, Tanzania, the National Insti-
tute of Medical Research in Dar es Salaam, Tanzania, and the University
TeachingHospital, Lusaka, Zambia. The study is registeredwithhttp://Clin-
icalTrials.gov (NCT01187719).
Eligible women received pMTCT ARV prophylaxis as recommended by
national Tanzanian or Zambian guidelines. Subjects started 300 mg of zi-
dovudine twice daily from 28 and 14 weeks of gestation in Tanzania and
Zambia, respectively, or as soon as possible thereafter pre-delivery. At the
onset of labour, women received 200 mg of single-dose nevirapine plus
300 mg of oral zidovudine every 3 h and 150 mg of lamivudine every 12 h
until delivery (Tanzania), or 600 mg of oral zidovudine and 300 mg of
lamivudine every 12 h until delivery (Zambia). Post-delivery, 300 mg of zi-
dovudine and 150 mg of lamivudine were taken twice daily for 7 days.
Newborns were given 2 mg/kg single-dose nevirapine suspension within
24–72 h after birth and then 4 mg/kg zidovudine syrup (Tanzania) or
2 mg/kg nevirapine suspension (Zambia) twice daily for 7 days. All the
women in the trial breastfed their children for 6 months and then
weaned them rapidly.
Womenwere randomized1:1 inaparallel groupdesign toeither thena-
tional standard of care or the national standard of care plus 184 mg of
phenytoin (2×92 mg tablets) once daily from the onset of labour for
7 days. The randomization sequence was generated by a trial statistician
from the MRC using simple randomization blocks. Participant codes and
allocations were held in secure envelopes stored by the project manager
at each site. At enrolment (pre-delivery), women were randomized by
the study doctor at the clinic by opening the next envelope. When the
woman presented in labour at the clinic, a study nurse confirmed and
recorded the time of ingestion of the study drug(s) by direct observation
of intake or by asking the woman if she had already taken the study
drug(s) at home.
Objectives, outcomes and follow-up
The primary objectives of the pilot study were to determine the effect of
7 daysofphenytoinadministrationon theeliminationhalf-lifeofnevirapine
and the development of nevirapine resistance in HIV-infected, pregnant
women receiving single-dose nevirapine as part of perinatal HIV preven-
tion. Theprimaryoutcomeswere thepharmacokinetic parametersof nevir-
apine (elimination half-life and time to achieve an undetectable plasma
concentration) and nevirapine resistance (primary nevirapine mutations
L100I, K101P, K103N/S, V106A/M, V108I, Y181C/I, Y188C/L/H and
G190A)16 at week 4–6. Secondary outcomes were all adverse events
(AEs) possibly or probably related to pMTCT ARV prophylaxis or phenytoin,
and HIV infection of the infant.
Haematologyandbiochemistry testswereperformedat enrolmentand
1 weekpost-partum.CD4cell countsandviral load (VL)wereassayedatde-
livery. Infants were tested just after birth (,30 min) and at week 4–6 by
DNA PCR assays. Blood was taken from the women and stored at delivery
and days 1, 3, 5, 7 and 14 post-partum, and from the children at delivery
and on day 7 post-delivery for the retrospective determination of plasma
concentrations of nevirapine (and phenytoin) at the Department of Phar-
macy,RadboudUniversityNijmegenMedical Centre,Nijmegen, TheNether-
lands. The nevirapine assay used HPLC with a lower limit of quantification
(LLOQ) of 0.05 mg/L,17 and phenytoin was determined by a validated im-
munoassay with an LLOQ of 0.4 mg/L. Nevirapine resistance was assayed
in plasma stored from samples at baseline and at week 4 in Tanzania and
week 6 in Zambia at the Department of Virology of the University Medical
Centre Utrecht, Utrecht, The Netherlands. Pharmacokinetic and resistance
assays were performed blinded to randomized allocation.
The sample size of 50 subjects (25 per arm) delivering in the study clinic
provided .80% power to detect a decrease of at least 27% in the elimin-
ation half-life of nevirapine associated with 7 days of phenytoin, allowing
a 20% drop-out rate (lack of follow-up samples, based on experience
from the VITA-1 trial).14
Safety analyses included all women who were observed or reported
taking studymedication (the safety population). Analyses of pharmacokin-
etics and resistance included the safety population who did not receive a
second dose of nevirapine, who delivered vaginally [rather than by caesar-
ean section (C/S)] and who had pharmacokinetic evidence (a detectable
plasmaconcentration1 daypost-delivery) of takingnevirapine, andpheny-
toin if this had been allocated (the protocol-specified primary pharmacoki-
netic population). Analyses were also carried out that included mothers
who delivered by C/S, as no difference in pharmacokinetic parameters
had been observed between C/S and vaginal deliveries in the VITA-1 trial.
Women in the control group with phenytoin detected in any sample were
excluded from the pharmacokinetic and resistance analyses. Pharmacoki-
netic analysis was performed using Phoenix 64 WinNonlin 6.3 (Pharsight
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Corporation, CA, USA) and statistical analysis using SPSS version 18.0 (SPSS
Inc.). Randomized groups were compared using t-tests for continuous
pharmacokinetic variables [after transformation to the log scale, i.e. com-
paring geometric means (GMs)], rank-sum tests for all other continuous
variables and exact tests for categorical variables.
Results
Study participants
Wescreened335HIV-infected,pregnantwomen fromJuly2010 to
June 2011; most of the 262 women not randomized were already
on cART (n¼94), had a CD4 cell count,350 cells/mm3 (n¼82) or
did not return after screening (n¼56) (Figure 1). Seventy-three
(22%) women were randomized: 35 and 37 were allocated to the
control and intervention groups, respectively. One woman had
been randomized twice, so the second randomization was
excluded and the woman followed the first randomization. The
demographic characteristics at enrolment and delivery were gen-
erally reasonably balanced between the two groups [Table 1 and
Table S1 (available as Supplementary data at JAC Online)], the
main difference being the significantly shorter time from nevira-
pine ingestion to delivery in the intervention group, which must
Excluded (n = 262)
• On cART (n = 94)
• CD4 <350 cells/mm3 (n = 82)
• Did not return to clinic (n = 56)
• Declined to participate (n = 14)
• Had sdNVP in previous pregnancy (n = 5)
• Took part in other trial (n = 4)
• Used medication that interferes
 with study drugs (n = 3)
• <18 years of age (n = 2)
• Not able to understand trial (n = 1)
• Not able to adhere to study
 schedule (n = 1)
Assessed for eligibility
(n = 335)
HIV-infected, ARV-naive, pregnant
women ≥18 years with CD4 >350
cells/mm3 randomized at 26-40
weeks of gestation (n = 73)
Double randomization (n = 1)
Allocated to the control group
(n = 35)
Allocated to the intervention group
(n = 37)
• LTFU before delivery (n = 4)
• Did not report to take study
 medication, because they
 were not noticed as VITA
 mothers when they
 delivered in clinic (n = 3)
• LTFU before delivery (n = 9)
• Did not report to take study
 medication, because they
 were not noticed as
 VITA mothers when they
 delivered in clinic (n = 2)
Delivered in the study clinic (n = 28)
Safety population
Delivered in the study clinic (n = 26)
Safety population
• No PK evidence for
 nevirapine (n = 3)
• LTFU: no PK samples (n = 2)
• No PK evidence for
 nevirapine (n = 2)
• No PK evidence for phenytoin
 (n = 1) 
PK data analysed (n = 23)
All women who delivered
Resistance data analysed (n = 21)
(missed week 6 visit (n = 1))
(sample failed to amplify (n = 1))
PK data analysed (n = 23)
All women who delivered
Resistance data analysed (n = 20)
(missed week 4/6 visit (n = 3))
Delivered by C/S (n = 7)
PK data analysed (n = 16)
Women who delivered vaginally (not
by C/S)
PK data analysed (n = 23)
Women who delivered vaginally (not
by C/S)
Figure 1. Profile of the VITA-2 trial (CONSORTdiagram). sdNVP, single-dose nevirapine; LTFU, lost to follow-up; PK, pharmacokinetic.
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have occurred by chance. This difference is, however, not expected
to have had an impact on our pharmacokinetic data, as the elimin-
ation half-life of nevirapine is long. In addition, no differenceswere
observed between the laboratory values at enrolment anddelivery
within either group (Table S1). The study finished once the recruit-
ment target had been met.
Pharmacokinetics
At delivery, considering only the women who delivered vaginally
(and not by C/S), there was no significant difference in plasma
concentration of nevirapine between the two groups [GM (95%
CI) was 1.08 (0.63–1.84) mg/L in the control patients versus 1.14
(0.70–1.86) mg/L in the intervention patients; GM ratio (GMR)
(90% CI) 1.05 (0.58–1.92), P¼0.82; t-test] (see Table S2, available
as Supplementary data at JAC Online). Plasma concentrations of
nevirapine subsequently decreased significantly more quickly
(Figure 2), and undetectable levels were reached significantly
earlier (Table 2), in the intervention group compared with the
control group. All results were similar, including womenwho deliv-
eredbyC/S, so results fromthe(larger)group includingwomenwho
delivered by C/S are subsequently presented.
One week post-delivery, plasma concentrations of nevirapine
were reduced in both groups, but to a significantly lesser extent
in the control group [GMR (1 week:delivery) (90% CI) 0.22 (0.18–
0.28), 20matchedpairs] thanthe interventiongroup [GMR(1week:
delivery) (90%CI)0.031 (0.026–0.038), 22matchedpairs].Overall,
levels were 85% lower in the intervention than the control group
[GMR (intervention:control) (90% CI) 0.15 (0.11–0.20), P,0.001;
t-test]. The GM (95% CI) elimination half-life of nevirapine was
63.2 (52.8–75.7) versus 25.5 (21.6–30.1) h in the control and
the intervention group, respectively (P,0.001; t-test), represent-
ing a 60% reduction [GMR (90% CI) 0.40 (0.33–0.49)]. The GM
(95% CI) time to achieve an undetectable nevirapine plasma con-
centration was 16.3 (13.8–19.3) versus 6.7 (5.7–7.8) days in the
control versus the intervention group (P,0.001; t-test). Conse-
quently, a significantly greater proportion of control group
women had detectable plasma levels of nevirapine at 1 week
and 2 weeks post-delivery (Table 2). All 23 (100%) women in the
control group versus 7/22 (32%) women in the intervention
group had a detectable plasma concentration of nevirapine at
1 week post-delivery (P,0.001; exact test) as did 11/21 (52%)
women in the control group versus 1/19 (5%) women in the inter-
vention group at 2 weeks post-delivery (P¼0.002; exact test).
The median (range) plasma concentration of phenytoin in all
the samples taken from delivery to 1 week post-delivery in the
intervention group was 1.5 (,0.4–24.7) mg/L. Twenty-one of 22
(95%) mothers had only subtherapeutic phenytoin levels (the
therapeutic range being defined as 10–20 mg/L).18 One (5%)
mother had an undetectable plasma concentration at delivery,
but her plasma level was detectable on day 1 and increased to
24.7 mg/L 1 week post-delivery. The median plasma level of
phenytoin in the infants was,0.4 (range,0.4–1.9) mg/L.
Resistance
Samples taken 4–6 weeks post-delivery were available from 21
control women (as one missed the week 6 visit, and for one
Table 1. Demographic characteristics of the women and infants in the VITA-2 trial
Control (n¼28) Intervention (7 days of phenytoin; n¼26) P value
At enrolment
age (years) 27 (23–31) 27 (23–33) 0.74
weight (kg) 62 (55–73) 66 (56–81) 0.11
BMI (kg/m2) 24.1 (21.7–27.9) 26.2 (23.3–30.9) 0.10
At delivery
gestational age at delivery (weeks) 39 (38–42) 39 (38–41) 0.78
CD4 cell count (cells/mm3) 366 (318–522) 412 (317–518) 0.76
HIV-1 RNA (copies/mL) 2832 (1000–26518) 2420 (1542–11261) 0.99
birth weight (kg) 3.0 (2.7–3.2) 3.0 (2.7–3.4) 0.87
time from nevirapine ingestion to delivery (h) 9.1 (2.5–12.6) 2.1 (1.0–4.9) 0.003
Data are presented as median (IQR) and were tested using rank-sum.
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Figure 2. GM plasma concentrations of nevirapine over time post-delivery
(all women who delivered including those who delivered by C/S).
Fillekes et al.
2612
 at K
atholieke U
niversiteit on February 8, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
woman sample amplification failed due to a low VL) and 20 inter-
vention women (as three missed the week 4–6 visit). One (5%) of
the 21women in the control group had one nevirapine-associated
resistance mutation (elimination half-life 123.5 h) that had not
been present at baseline, versus 1/20 (5%) with one
nevirapine-associated resistance mutation in the intervention
group. However, themutation in the patient from the intervention
group was already present in a sample stored at delivery. Both
mutations were detected as mixtures with the wild-type nucleo-
tide sequence (V106MV in the control group, and K103KN in the
intervention group).
Safety
The 28 control and 26 intervention mothers gave birth to 30 (two
pairs of twins) and 28 (two pairs of twins) babies, respectively.
Twenty-one (one pair of twins) and 19 (one pair of twins) infants,
respectively, were tested just after birth and at week 4–6 post-
delivery. The overall transmission rate was 0/21 (0%) in the
control group and 1/19 (5%) in the intervention group. However,
the infected child tested positive at birth and must therefore
have been infected during the intrauterine period. In the infants,
10 clinical AEs were reported: four in the control group (n¼1
grade 1, n¼1 grade 2 and n¼2 grade 4) and six in the intervention
group (n¼1grade1,n¼1grade2,n¼1grade3andn¼3grade4).
The grade 4 AEs were a hospitalization for overweight after birth
and a death just after birth due to congenital malformation in
the control group, and three stillbirths (two fresh and one macer-
ated) in the intervention group.
Both platelet (P,0.001) and alanine transaminase (P,0.001)
levels increased significantly between enrolment and 1 week
post-delivery in each randomized group, but there was no differ-
ence between randomized groups in any laboratory safety param-
eter 1 week post-delivery (P.0.05). In total, 29 laboratory AEs
were reported:n¼14 in the control group versusn¼15 in the inter-
vention group (P¼1.0; exact test). Most were grade 1 (n¼11 in
each group), but four (n¼2 in each group) were grade 2, one was
grade 3 (intervention) and two were grade 4 (haemoglobin
,6.5 g/dL; one in each group). Eight clinical AEs were reported:
three in the control group [n¼1 grade 2, n¼1 grade 3 and n¼1
grade 4 (an emergency C/S)] and five in the intervention group
(n¼1 grade 1, n¼3 grade 2 and n¼1 grade 3). None of the labora-
tory and clinical AEs in themothers or infants was judged possibly
or probably related to the study medication.
Discussion
Here we demonstrate that adding a 7 day course of phenytoin, as
an enzyme inducer, from the onset of labour produces a large and
significant reduction in the elimination half-life of nevirapine in
HIV-infected, pregnant women using single-dose nevirapine as
part of their pMTCT ARV prophylaxis. Seven days of phenytoin ad-
ministration was safe and effective, with no new nevirapine resist-
ance mutations observed.
Importantly, plasma concentrations of nevirapine at delivery
were similar in those receiving and not receiving phenytoin, and
also comparable to those in reported previous studies,5,13 similar
to our previous study evaluating a single dose of carbamazepine
as an enzyme inducer.14 The time lag in enzyme inducer effect
Table 2. Maternal nevirapine plasma concentrations at delivery, week 1 and week 2 for women in the VITA-2 trial, including women who delivered by
C/S
Women who delivered, including women who delivered by C/S
control intervention P value GMR (90% CI)
At delivery
samples taken, n 20 22
nevirapine plasma concentration (mg/L), GM (95% CI) 1.02 (0.58–1.78) 1.14 (0.70–1.86) 0.76a 1.12 (0.61–2.03)
,0.05 mg/L nevirapine, n (%) 1 (5) 1 (5)
1 week after delivery
samples taken, n 23 22
nevirapine plasma concentration (mg/L), GM (95% CI) 0.23 (0.18–0.31) 0.035 (0.027–0.046) ,0.001a 0.15 (0.11–0.20)
,0.05 mg/L nevirapine, n (%) 0 (0) 15 (68) ,0.001b
women with 1 week and delivery samples, n 20 22
nevirapine plasma concentration 1 week:delivery, GMR (90% CI) 0.22 (0.18–0.28) 0.031 (0.026–0.038)
2 weeks after delivery
samples taken, n 21 19
nevirapine plasma concentration (mg/L), GM (95% CI) 0.044 (0.031–0.062) 0.026 (0.024–0.029) 0.006a 0.59 (0.44–0.80)
,0.05 mg/L nevirapine, n (%) 10 (48) 18 (95) 0.002b
women with week 2 and delivery samples, n 18 18
nevirapine plasma concentration 2 weeks:delivery, GMR (90% CI) 0.030 (0.026–0.034) 0.022 (0.015–0.031)
Median nevirapine plasma concentrations are similar to the GM and are therefore not shown in Table 2.
at-test.
bExact test.
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reflects the time required for transcription of CYP enzymes and
protein synthesis. The delay in enzyme induction and the fact that
phenytoin minimally penetrates into breast milk therefore ensures
that theprotectiveperinataleffectof single-dosenevirapine ismain-
tained. The absence of HIV transmission during the post-partum
period, similar to or even lower than rates in previous studies,10
also confirms the efficacy of the pMTCT regimen.
Post-delivery, the pharmacokinetic parameters of nevirapine
were substantially affected by enzyme induction. Adding phenytoin
to single-dose nevirapine reduced plasma levels of nevirapine by
85% and produced a significantly larger proportion of women with
undetectable nevirapine levels 1 week and 2 weeks post-delivery.
Both effects are a consequence of the 60% reduction in the elimin-
ation half-life of nevirapine, an absolute difference of 35.8 h. This is
the largestdecline ineliminationhalf-lifeofnevirapineever reported,
especially in the target population of HIV-infected, pregnant
women. For example, the pilot study of L’Homme et al.13 found a
median elimination half-life reduction of 38% (219.4 h) in four
healthy Dutch women receiving single-dose nevirapine with
7 days of phenytoin administration, and a single-dose of carba-
mazepine reduced nevirapine levels by 36% in HIV-infected, preg-
nant women receiving single-dose nevirapine.14 Not surprisingly, a
7 day course of an enzyme inducer has a greater effect than a
single dose alone on the elimination half-life of nevirapine in
HIV-infected, pregnant women.
The mechanisms by which the CYP enzymes are induced
involves the transcription factors pregnane X receptor and the
constitutive androstane receptor. The enzyme inducer binds to
these receptors, thereby stimulating activation of the CYP
enzyme.19 Studies have shown that CYPenzyme induction is corre-
lated with dose and drug level,20 with higher doses and a higher
plasma level of the enzyme inducer resulting in lower serum
levels of the test drug. This probably explains why induction of
the CYP enzyme has a greater effect with a long course of an
enzyme inducer thanwithonly the single doseused in our previous
study.
Although current guidelines, including zidovudine monotherapy
pre-delivery and 7 days of zidovudine/lamivudine post-delivery,
are complex, they have substantially reduced the emergence of
nevirapine resistance by protecting the subtherapeutic nevirapine
‘tail’, since the lengthy duration of low and subtherapeutic levels
of nevirapine in the blood is plausibly associated with increases in
nevirapine resistance. A meta-analysis estimated that 4.5% of
women using single-dose nevirapine and additional ARVs post-
partum showed nevirapine resistance 4–8 weeks post-partum.4
In our study, the overall prevalence of new nevirapine resistance
was2.4%(1outof41samples);althoughweobservednonevirapine
resistance mutations after single-dose nevirapine in combination
with 7 days of phenytoin, the numbers are clearly too low to make
any conclusions about nevirapine resistance on the basis of this
study alone. However, it raises the prospect that full elimination of
nevirapine resistance could be possible. In the VITA-1 trial, we
foundthatwomenwithundetectablenevirapineplasmaconcentra-
tions 1 week post-delivery were less likely to develop nevirapine re-
sistance mutations, and that the elimination half-life in women
with new nevirapine mutation(s) was almost two and five times
longer than the median half-lives in the control and intervention
groups, respectively. Thus, it is plausible that adding a 7 day
course of phenytoin at the onset of labour might have significant
additional benefits in reducing the selectionofnevirapine resistance
mutations, even on top of the current ARV prophylaxis ‘tail’.
Themain limitation of the studywas its relatively small size. The
trial was designed as a pilot powered to detect a difference
between the intervention and control groups in the elimination
half-life of nevirapine. A much larger sample size (200; 100 per
arm) would be needed to detect significant differences in
the development of nevirapine resistance between the two
groups. However, this group of women is extremely challenging
to recruit and retain (see Figure 1): only 22% of those assessed
for eligibility pre-delivery were randomized, a further 26% of
those randomized dropped out before delivery, and a further 24%
of those who delivered in the study clinic did not provide samples
4–6 weeks post-delivery. We would therefore have needed to
screen 1600 women to achieve 200 women with week 4–6
samples. Although a larger Phase III trial should ideally confirm
the efficacy of 7 days of phenytoin treatment on resistance as a
primary outcome, the substantial significant reductions in nevira-
pine half-life, coupled with previous clinical and sophisticated
modelling studies6,7 demonstrating a causal association between
the half-life of nevirapine and the emergence of resistance,
suggests that it is highly likely to be effective. Another limitation
was the standard HIV genotyping assay used, which only detects
mutations present in.20% of the viral population and not subpo-
pulations of mutants. Deep sequencing of these samples is
planned.
It is estimated that 18%–64% of the women living in sub-
SaharanAfricawithHIVare receivingcART forpMTCT,asnowrecom-
mended by the WHO (Option B+). However, this means that thou-
sands of women are still receiving single-dose nevirapine21 and
demonstrates the challenge of widespread implementation of the
current guidelines. Phenytoin can be used safely during pregnancy
and breastfeeding22 and side effects are expected to be infrequent
using sucha lowdose foronlya short period.Where it is not possible
to provide cART, phenytoin is cheap and available in almost every
clinic. Phenytoin may also be a useful intervention when women
stop nevirapine at the end of breastfeeding within Option B+. We
have demonstrated that the implementation of this intervention
would substantially and significantly reduce the half-life of nevira-
pine; previous data demonstrating a causal relationship between
nevirapine half-life and emergence of resistance 6,7,14 suggest that
implementationwouldnotonly facilitatethereductionofnevirapine
resistance, but also enable further increases in coverage for preg-
nant women in need of perinatal HIV prophylaxis, while probably
retaining the benefits of single-dose nevirapine in reducing trans-
mission. This strategy might therefore support the overarching
goal of the technical consultation of the WHO to reduce the
overall HIV transmission rate frompMTCT to,5%at the population
level by the end of 2015.
In summary, the addition of an enzyme inducer for 7 days to
single-dose nevirapine for pMTCT greatly reduced the presence of
subtherapeutic nevirapine levels by significantly shortening the
elimination half-life of nevirapine, with no new nevirapine resist-
ancemutations observed. Since prolonged subtherapeutic nevira-
pine exposure is known to lead to the emergence of nevirapine
resistance,6,7,14 and since phenytoin is safely and widely used in
women15 to minimize HIV transmission from mother to child,
single-dosenevirapine couldbeusedwithphenytoinas analterna-
tive if other ARV drugs were unavailable.
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